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Abstract
Background Coformulated elvitegravir, cobicistat,
emtricitabine, and tenofovir disoproxil fumarate (EVG/
COBI/FTC/TDF; Stribild) is a recommended integrase
inhibitor-based regimen in treatment guidelines from the
US Department of Health and Human Services and the
British HIV Association. The purpose of this analysis was
to determine the change in patient-reported symptoms over
time among HIV-infected adults who switch to Stribild
versus those continuing on a protease inhibitor (PI) with
FTC/TDF.
Methods A secondary analysis was conducted on the
STRATEGY-PI study (GS-US-236-0115, ClinicalTrials.
gov NCT01475838), a randomized, open-label, phase 3b
trial of HIV-infected adults taking a PI with FTC/TDF who
were randomly assigned (2:1) either to Stribild (switch) or
continuation of their existing regimen (no-switch). Logistic
regressions and longitudinal modeling were conducted to
evaluate the relationship of treatment with bothersome
symptoms.
Results At week 4 as compared with baseline, the switch
group experienced a statistically significantly lower
prevalence in five symptoms (diarrhea/loose bowels,
bloating/pain/gas in stomach, pain/numbness/tingling in
hands/feet, nervous/anxious, and trouble remembering).
The lower prevalence of diarrhea/loose bowels, bloat-
ing/pain/gas in stomach, and pain/numbness/tingling in
hands/feet observed at week 4 was maintained over time.
While there were no significant differences between groups
in the prevalence of sad/down/depressed and problems with
sex at week 4 or week 48, longitudinal models indicated
the switch group had a statistically significantly decreased
prevalence in both symptoms from week 4 to week 48. As
compared with the no-switch group, higher levels of sat-
isfaction with treatment were experienced by patients in the
switch group at the first follow-up visit and at week 24.
Conclusions In this study sample, a switch from a riton-
avir-boosted PI, FTC, and TDF regimen to coformulated
EVG/COBI/FTC/TDF was associated with more treatment
satisfaction and a reduction in the prevalence of patient-
reported diarrhea/loose bowel symptoms, which was
maintained over the 48-week study period.
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Key Points for Decision Makers
Little is known about how HIV patients’ symptoms
change after switching to Stribild versus continuing
a regimen consisting of a protease inhibitor with
emtricitabine and tenofovir disoproxil fumarate.
In this study, switching to Stribild was associated
with significant, maintained improvements from
baseline to 48 weeks in three patient-reported HIV
symptoms: diarrhea/loose bowels, bloating/pain/gas
in stomach, and pain/numbness/tingling in hands/
feet.
Higher levels of satisfaction with treatment were
experienced by patients who switched to Stribild
compared with the no-switch group at the first
follow-up visit, and those treated with Stribild
also reported greater treatment satisfaction at week
24.
1 Introduction
Effective combination antiretroviral therapy (cART) has
led to significant declines in HIV/AIDS-related morbidity
and mortality. The success of cART is highly dependent on
patient adherence to therapy, which may be influenced by a
variety of factors, including regimen complexity and
treatment tolerability [1]. Experiencing symptoms related
to treatment and/or disease increases the risk for undesir-
able clinical outcomes, including hospitalization, lower
health-related quality of life, and shortened survival [2].
Guideline-recommended cART regimens differ not only in
complexity (number of prescribed pills, frequency of dos-
ing, food requirements) [3], but also tolerability. One
strategy to improve the complexity of cART is regimen
simplification, a change in established effective therapy to
reduce pill burden and/or dosing frequency [4], which may
also improve treatment tolerability and adherence because
of the unique side effect profile of each antiretroviral
medication.
Switching from a multi-tablet regimen to a single-tablet
regimen is one type of regimen simplification, and might
be a useful option for virologically suppressed patients on a
multi-tablet cART regimen. In addition to simplicity, some
newer single-tablet regimens may be better tolerated by
patients. Switching to a coformulated single-tablet regimen
consisting of elvitegravir, cobicistat, emtricitabine, and
tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF;
Stribild, STB) has demonstrated non-inferiority efficacy
[HIV-1 ribonucleic acid (RNA)\50 copies/mL] at week 48
compared with continuation of multi-tablet ritonavir
(RTV)-boosted protease inhibitor (PI), FTC, and TDF
regimen in virologically suppressed adults [5]. The symp-
tom experience of patients switching to EVG/COBI/FTC/
TDF compared with the symptom experience of those who
continue a multi-tablet RTV-boosted PI regimen has not
been determined. This analysis describes changes in
patient-reported symptoms over 48 weeks in virologically
suppressed HIV-infected adults who simplified therapy to
EVG/COBI/FTC/TDF versus those who remained on a
multi-tablet RTV-boosted PI, FTC, and TDF regimen, as
well as a comparison of patient-reported satisfaction
between the two regimens.
2 Methods
2.1 Study Design
Details regarding the study design and patient recruitment
have been previously described [5] and are summarized
here. STRATEGY-PI (ClinicalTrials.gov NCT01475838)
was an international, open label, randomized study, which
evaluated the efficacy (non-inferiority), safety, and tolera-
bility of switching to the single-tablet regimen STB con-
taining EVG 150 mg, COBI 150 mg, FTC 200 mg, and
TDF 300 mg, from a regimen consisting of an RTV-
boosted PI, FTC, and TDF (PI ? RTV ? FTC/TDF) in
virologically suppressed HIV-1 infected subjects. Between
December 12, 2011, and December 20, 2012, 433 partici-
pants were randomly assigned (2:1) and dosed; 293 swit-
ched to the simplified regimen of STB (switch group) and
140 remained on their baseline PI-containing regimen (no-
switch group). After exclusions, 290 and 139 participants,
respectively, were analyzed in the modified intention-to-
treat population. Post-baseline study visits occurred at
weeks 4, 8, 12, 24, 36, and 48. Participants and investi-
gators were not masked to the treatment allocation in this
open-label study.
2.2 Baseline Demographics and Clinical
Characteristics
Demographics (gender, age, race, and ethnicity) and clin-
ical characteristics [serious mental illness, cluster of dif-
ferentiation 4 (CD4) cell count, asymptomatic status, years
since HIV diagnosis, years since first antiretroviral therapy
use, on first antiretroviral regimen, PI used at randomiza-
tion, the Veterans Aging Cohort Study (VACS) Index, and
Fibrosis (FIB)-4 score] were collected or calculated.
446 J. Gathe et al.
Serious mental illness was defined as a diagnostic history
of one or more of the following conditions based on
medical chart review: major depression, anxiety,
schizophrenia, bipolar disorder, post-traumatic stress dis-
order, or other psychosis. The VACS Index was calculated
to quantify the overall mortality risk associated with HIV.
The VACS Index is a summary score based on age, CD4
count, HIV-1 RNA, the FIB-4 score, creatinine, and viral
hepatitis C infection to predict all-cause and cause-specific
mortality and other outcomes in those living with HIV
infection and mortality among those without HIV infection
[6]. The FIB-4 score is computed using age, platelet,
aspartate and alanine transaminase values, and provides an
estimate of the degree of liver fibrosis in HIV and hepatitis
C virus co-infected patients [7].
At the enrollment visit, study subjects were asked to
endorse the reason(s) they chose to enroll in the study.
Options included (a) ‘‘Desire to simplify your current anti-
HIV regimen’’; (b) ‘‘I am not tolerating the current regimen
well because of side effects’’; (c) ‘‘I am concerned about
the long-term side effects of my current anti-HIV regi-
men’’; (d) ‘‘I am having trouble taking my current regimen
on a regular basis’’; and (e) ‘‘Other.’’
2.3 Patient-Reported Outcomes (PROs)
2.3.1 HIV Symptom Index (HIV-SI)
The dependent variable in this study was the HIV Symp-
tom Index (HIV-SI). The HIV-SI is a validated patient-
reported outcome (PRO) instrument that assesses the
symptom burden of 20 common HIV symptoms associated
with HIV treatment or disease [8]. The instrument was
developed on the basis of literature review and clinical and
advisory board feedback, is supported by evidence of good
construct validity, and has been considered the gold stan-
dard in contemporary HIV symptom research [9]. Patients
are asked about their experience with each symptom during
the past 4 weeks using a 5-point Likert-type scale.
Response options and scores are as follows: (0) ‘‘I don’t
have this symptom’’; (1) ‘‘I have this symptom and it
doesn’t bother me’’; (2) ‘‘I have this symptom and it
bothers me a little’’; (3) ‘‘I have this symptom and it
bothers me’’; (4) ‘‘I have this symptom and it bothers me a
lot.’’
The 20 symptoms comprising the HIV-SI are fatigue/
loss of energy, difficulty sleeping, nervous/anxious, diar-
rhea/loose bowels, changes in body composition, sad/-
down/depressed, bloating/pain/gas in stomach, muscle
aches/joint pain, problems with sex, trouble remembering,
headaches, pain/numbness/tingling in hands/feet, skin
problems/rash/itching, cough/trouble breathing, fever/
chills/sweats, dizzy/lightheadedness, weight loss/wasting,
nausea/vomiting, hair loss/changes, and loss of appetite/-
food taste.
Consistent with prior analyses by Edelman et al. [10],
symptoms were dichotomized into a 0 (not present or no
bother) or 1 (bothered 2, 3, or 4) scale for individual pre-
sentation in order to provide information about symptoms
not only present but bothersome and, thus, clinically rele-
vant to treatment decisions. In addition, the overall both-
ersome symptom count at baseline was generated by
counting the number of individual symptoms scored as
bothersome and used as a covariate in regression analyses
and longitudinal modeling.
2.3.2 Descriptive PRO Measures
A number of PRO instruments were used to provide
descriptive information and also served as covariates in
regression and longitudinal analyses. The Physical Com-
ponent Summary (PCS) and Mental Component Summary
(MCS) from the Short Form 36 (SF-36), an instrument
supported by extensive evidence of good psychometric
properties in a range of therapeutic areas [11], including
HIV-infected individuals [12], were used to describe
health-related quality of life [13]; the Visual Analog Scale
(VAS) Adherence Questionnaire [14], a validated instru-
ment that correlates significantly with Medication Event
Monitoring System caps and pharmacy data, was used to
assess patient-reported adherence to their antiretroviral
regimen using a linear scale (0–100 %) to indicate what
proportion of medications was taken in the last 30 days;
and the HIV Treatment Satisfaction Questionnaire
(HIVTSQ), a ten-item instrument with five items assessing
general treatment satisfaction and five items assessing
treatment ease [15], was used and is supported by evidence
of good internal consistency and reliability [16]. The status
form (HIVTSQs) was used at baseline and asks about
‘‘now,’’ and the change form (HIVTSQc), in which items
state ‘‘compared to before,’’ was used at week 4 and week
24. For the HIVTSQs form, the response options are
anchored at 6 and 0, and for the HIVTSQc form, answers
range from values of 3 to -3. The total score ranges from 0
to 60 for the status form at baseline and from -30 to 30 for
the change form, with higher positive scores indicating
more/improved satisfaction and higher negative scores
indicating greater dissatisfaction.
2.4 Statistical Analysis
Analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC, USA). Questionnaires were submitted
by 96 % of enrolled patients at baseline and 80 % at week
48, the decline due in part to patients that left the study. Of
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the questionnaires received, there were roughly 140 items
with missing values, of a total of 170,000 records
(\0.1 %). As in the analyses completed for the STRAT-
EGY-non-nucleoside reverse transcriptase inhibitors
(NNRTI) trial [17], imputation rules were applied to the
HIV-SI data. If multiple responses were provided for a
single item, the most severe (maximum) of the responses
was used (Justice A., personal communication, July 28,
2014). For single items that were left blank, but with other
items completed, the missing value was imputed to ‘‘I do
not have this symptom,’’ a score of 0 [10].
Descriptive statistics were used to describe baseline
demographic and clinical characteristics and PROs.
Unadjusted and adjusted analyses at week 4 and week 48
were performed to evaluate the relationship of treatment
with the probability of experiencing HIV-SI items, with
and without covariates. Specifically, HIV-SI symptoms
were modeled as binary outcomes using a logistic regres-
sion model analysis. Each model included treatment as the
independent variable and covariates which were selected
from a number of potential demographic, clinical, and
descriptive variables that were evaluated for
multicollinearity.
Longitudinal modeling was performed using generalized
mixed models to show symptom patterns over each of the
seven study visits using data from the HIV-SI. The func-
tional form of the change pattern was assessed visually
from the observed prevalence in each group. Linear and
quadratic patterns were tested to determine optimal fit,
ultimately favoring a linear function. As with the
STRATEGY-NNRTI trial [17], the decision was made to
model the data from weeks 4 through 48 and include
baseline as a covariate. To assess the possibility that the
effect of treatment may itself vary over time, the models
included an interaction between treatment and time in
addition to the indicator of a simple treatment group.
Continuous variables were mean centered for ease of
interpretation and model fit. The fit of the derived models
were compared with a simple unadjusted model that
included time and treatment, along with a random intercept
to account for the longitudinal nature of the data. The




Baseline demographics and clinical characteristics were
similar in the two treatment groups (Table 1). At ran-
domization, the majority of subjects in the switch group
and no-switch group were taking atazanavir [n = 123
(42 %) and n = 51 (37 %), respectively] or darunavir
[n = 113 (39 %) and n = 60 (43 %), respectively]. In the
switch group versus the no-switch group, participants had a
mean duration of 6 versus 5 years since HIV diagnosis and
3 years since first antiretroviral therapy use, and 73 versus
75 % were asymptomatic, respectively. The majority of
patients in both groups combined (86 %) reported that the
reason they chose to enroll in the study was a ‘‘Desire to
simplify your current anti-HIV regimen.’’
3.2 Descriptive Analysis of PRO Measures
At baseline, the prevalence rates of all 20 bothersome symp-
toms on the HIV-SI were similar between groups (Table 2). In
the switch group, the prevalence rates of eight symptoms
(nervous/anxious, diarrhea/loose bowels, changes in body
composition, bloating/pain/gas in stomach, muscle aches/joint
pain, problems with sex, pain/numbness/tingling in hands/feet,
and fever/chills/sweats) were significantly lower at week 4
comparedwith baseline; atweek 48, the prevalence of only half
of these symptoms (diarrhea/loose bowels, changes in body
composition, bloating/pain/gas in stomach, and fever/chills/
sweats) remained significantly lower. In the no-switch group,
the prevalence rates of three symptoms (headaches, fever/
chills/sweats, andweight loss/wasting)were significantly lower
atweek4comparedwithbaseline; atweek48, theprevalenceof
only oneof these symptoms (headaches) remained significantly
lower.
Satisfaction with treatment was similar between groups
at baseline. At weeks 4 and 24, the mean HIVTSQc scores
were positive for both groups, indicating greater satisfac-
tion with treatment; however, the scores for the switch
group were statistically significantly higher compared with
the no-switch group [mean (SD) at week 4: switch group
21.5 (9.4) and no switch group 13.3 (11.8), p\ 0.001;
mean (SD) at week 24: switch group 23.1 (8.8) and no
switch group 14.5 (12.9), p\ 0.001]. SF-36 PCS scores
were high at baseline for the switch and no-switch groups
[mean (SD) 54.5 (6.3) vs. 54.4 (7.2), respectively,
p = 0.71], while MCS scores were just below US popu-
lation norms for both groups [mean (SD) 48.9 (11.6) vs.
49.4 (10.0), respectively, p = 0.79]. At week 48, the PCS
and MCS mean scores were largely unchanged for the
switch and no-switch groups [PCS change from baseline,
mean (SD) 0.5 (5.8) vs. -0.2 (5.2), respectively, p = 0.52;
MCS change from baseline, mean (SD) -0.1 (8.9) vs. -1.4
(6.8), respectively, p = 0.25], and there were again no
differences observed between the switch and no-switch
groups [PCS, mean (SD) 54.8 (6.8) vs. 54.3 (7.5), respec-
tively, p = 0.69; MCS, mean (SD) 48.6 (12.1) vs. 49.0
(10.7), respectively, p = 0.79]. Patient-reported treatment
adherence was C97 on the 100-point VAS across study
visits in both treatment groups.
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3.3 Associations Between HIV-SI Bothersome
Symptoms and Treatment in Logistic
Regression Models and Longitudinal Analyses
The association between treatment and each bothersome
symptom was examined by logistic regression models and
longitudinal analyses. In the final models, treatment group
(switch vs. no-switch) was the independent variable and
covariates included age, sex, race (white vs. non-white),
baseline bothersome symptom count, VACS Index score,
years since HIV diagnosis, years since first antiretroviral
therapy use, baseline PI use, serious mental illness, and
baseline MCS and PCS scores. Treatment adherence was
not considered a covariate because nearly all participants
across groups reported nearly perfect levels of adherence.
The adjusted logistic regression models show that
switching to STB was associated with a lower risk of
experiencing five bothersome symptoms (diarrhea/loose
bowels, bloating/pain/gas in stomach, pain/numbness/tin-
gling in hands/feet, nervous/anxious, and trouble
Table 1 Patient-reported baseline demographics and clinical characteristics
Switch group (N = 293) No-switch group (N = 140) p value
Male, n (%) 250 (85.3) 121 (86.4) 0.76
Age, mean (SD) 41 (9.7) 41 (8.9) 0.99
Racea, n (%) 0.72
White 234 (79.9) 113 (80.7)
Non-white 57 (19.5) 25 (17.9)
Ethnicity, n (%) 0.50
Hispanic or Latino 42 (14.3) 17 (12.1)
Serious mental illnessb, n (%) 28 (9.6) 13 (9.3) 0.93
VACS Index scorec, mean (SD) 9.2 (9.9) 8.0 (8.5) 0.33
FIB-4 scored, mean (SD) 0.9 (0.3) 0.9 (0.4) 0.67
Asymptomatic, n (%) 214 (73.0) 105 (75.0) 0.66
CD4 cell count (cells per lL), mean (SD) 604 (274.6) 624 (269.9) 0.25
Years since HIV diagnosis, mean (SD) 6.0 (4.8) 5.0 (3.6) 0.79
Years since first antiretroviral therapy use, mean (SD) 3.0 (2.8) 3.0 (2.2) 0.23
On first antiretroviral therapy regimen at randomization, n (%) 226 (77.1) 116 (82.9) 0.17
Protease inhibitor at randomization, n (%) 0.56
Atazanavir 123 (42.0) 51 (36.7)
Darunavir 113 (38.6) 60 (43.2)
Lopinavir 49 (16.7) 23 (16.5)
Fosamprenavir 6 (2.0) 5 (3.6)
Saquinavir 2 (0.7) 0 (0.0) 0.80
HIV-SI symptom counte, mean (SD) 4 (4.5) 4 (4.4) 0.80
SF-36 PCSf, mean (SD) 54.5 (6.3) 54.4 (7.2) 0.71
SF-36 MCSf, mean (SD) 48.9 (11.6) 49.4 (10.0) 0.79
For categorical data, p value was from the CMH test (using the general association statistic). For continuous data, p value was from the two-sided
Wilcoxon rank sum test. p value comparing protease inhibitor at randomization compared the distribution of all five drugs, and did not focus on
individual drugs
CMH Cochran-Mantel-Haenszel, FIB-4 Fibrosis 4, HIV-SI HIV Symptom Index, SD standard deviation, SF-36 MCS Short Form 36 Mental
Component Summary, SF-36 PCS Short Form 36 Physical Component Summary, VACS Veterans Aging Cohort Study
a Two subjects in the switch group and two subjects in the no-switch group did not provide race data
b Serious mental illness defined as having a history of one or more of the following diagnoses based on chart review: major depression, anxiety,
schizophrenia, bipolar disorder, post-traumatic stress disorder, or other major psychiatric disorders
c The VACS Index score is a score that sums points for age, CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine transaminase,
creatinine, and viral hepatitis C infection
d The FIB-4 score is derived from age and platelet, aspartate and alanine transaminase values
e The HIV-SI bothersome symptom count is a summation of the presence of the individual HIV-SI items and ranges from 0 to 20, with higher
counts indicating more bothersome symptoms
f The SF-36 PCS and MCS are scored from 0 to 100, with higher scores indicating better health
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remembering) at week 4 (see ESM Table 1 in the Elec-
tronic Supplementary Material). This association, however,
was maintained only for diarrhea/loose bowels at week 48.
As indicated in unadjusted and adjusted models, the no-
switch group did not have a significantly lower prevalence
in any symptom at week 4 or week 48 as compared with the
switch group.
The prevalence of bothersome symptoms over time was
evaluated using mixed-effects logistic models adjusted for
the same covariates as those specified above. In all
instances, the BIC of the multivariate model showed a
substantial improvement in fit over the simple unadjusted
model with treatment only, suggesting that bothersome
symptom prevalence was associated with at least some of
the predictors included in the model.
The adjusted longitudinal models revealed a statistically
significant difference in the prevalence of five symptoms
(diarrhea/loose bowels, bloating/pain/gas in stomach, pain/
numbness/tingling in the hands/feet, sad/down/depressed,
and problems with sex) between the switch and no-switch
groups over time, all favoring the switch group. A com-
plete table showing the coefficients, including findings for
main effects and time by treatment interactions (the effect
of time depends on whether the subject was in the switch or
no-switch group), is provided in ESM Table 2 in the
Electronic Supplementary Material. No covariate was sig-
nificant in all symptom models; however, the presence of
the bothersome symptom at baseline, the HIV-SI symptom
count at baseline, and SF-36 MCS score at baseline were
significant for most symptom models. Table 3 summarizes



















Fatigue/loss of energy 35.7 42.2 34.5 34.9 33.6 33.3
Difficulty sleeping 31.5 29.6 28.1 34.1 29.4 27.5
Nervous/anxious 30.4 28.9 22.1** 27.1 26.0 20.8
Diarrhea/loose bowels 29.0 27.4 13.5***,^^^ 31.0^^^ 11.3***,^^^ 25.8^^^
Changes in body
composition
28.3 25.9 18.5*** 24.8 23.4* 20.0
Sad/down/depressed 27.6 23.7 24.6 26.4 25.3 25.0
Bloating/pain/gas in
stomach
26.2 23.7 18.5**,^^ 31.0^^ 20.0* 24.2
Muscle aches/joint
pain
25.5 25.2 17.1** 21.7 20.4 18.3
Problems with sex 25.5 20.0 20.3* 20.2 20.8 21.7
Trouble remembering 20.6 25.9 18.9 24.8 24.9 24.2
Headaches 18.9 20.7 16.0 13.2* 17.4 11.7*
Pain/numbness/
tingling in hands/feet
18.9 19.3 12.5**,^ 20.9^ 17.7 18.3
Skin problems/rash/
itching
17.1 17.0 15.3 14.7 18.9 16.7
Cough/trouble
breathing
15.0 11.1 13.5 10.9 11.3 12.5
Fever/chills/sweats 14.0 13.3 8.2** 7.0* 9.1* 8.3
Dizzy/lightheadedness 11.9 16.3 13.2 12.4 10.9 11.7
Weight loss/wasting 11.5 14.1 10.0 5.4** 9.4 7.5
Nausea/vomiting 11.2 5.9 7.5 5.4 6.4 7.5
Hair loss/changes 10.1 11.1 8.2 12.4 13.6 12.5
Loss of appetite/food
taste
5.9 5.9 7.8 3.1 7.9 5.8
* p\ 0.05, ** p\ 0.01, *** p\ 0.001 McNemar test within group for change from baseline
^ p\ 0.05, ^^p\ 0.01, ^^^p\ 0.001 Chi square test between group differences
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the results for symptoms with statistically significant
findings in the regression and/or longitudinal analyses.
Figure 1 shows the observed prevalence of each symptom
from Table 3 over time by treatment group.
With respect to diarrhea/loose bowels, the decreased
prevalence in the switch group is maintained over the study
period and is significantly lower than baseline from week 4
to week 48. With regard to bloating/pain/gas in stomach
and pain/numbness/tingling in hands/feet, the decreased
prevalence observed in the switch group was maintained
over the study period, and no further significant changes in
prevalence from week 4 to week 48 were observed. For
nervous/anxious, there is initially a significant decrease in
prevalence for the switch group; however, the difference is
not maintained over time because both groups decrease in
prevalence from week 4 to 48. For trouble remembering,
the switch group’s initial decrease in prevalence was not
maintained over time, and no differences in prevalence
were observed between the two groups from week 4 to
week 48. Finally, for both sad/down/depressed and prob-
lems with sex, there were no significant differences
between groups in the prevalence of either symptom at
week 4 or week 48; however, the longitudinal models
revealed that compared with the no-switch group, the
switch group had a statistically significant decreased
prevalence from week 4 to week 48.
4 Discussion
This study was the first prospective randomized HIV
switch trial to use the HIV-SI to assess the symptom
experience of patients switching from an RTV-boosted PI
to STB. The results indicate that switching to STB was
associated with more treatment satisfaction, improvements
in a number of patient-reported HIV symptoms that were
maintained over 48 weeks, and no differences or changes
in health-related quality of life.
Results of the descriptive analyses showed that diarrhea/
loose bowels, bloating/pain/gas in stomach, and pain/
numbness/tingling in hands and feet were statistically sig-
nificantly less prevalent for the switch group at week 4.
Adjusted logistic regression results were similar, with the
addition of lower prevalence for nervous/anxious and
trouble remembering. Of these affected symptoms, the
lower prevalence of diarrhea/loose bowels for the switch
compared with the no-switch group was maintained over
the study period from week 4 to week 48. This was the only
symptom with this finding—both a maintained advantage
over the no-switch group and a significantly lower expe-
rience in prevalence throughout measurement periods as
compared with baseline.
Drug-induced gastrointestinal (GI) side effects like
diarrhea or loose stool, most commonly associated with
the use of PIs like RTV, is a nuisance complication of
HIV therapy [18]. The mechanisms for PI-associated GI
dysfunction include increased calcium-dependent chlo-
ride conductance, cellular apoptosis and necrosis, and
decreased proliferation of intestinal epithelial cells [19].
The findings from the present study, a prominent reduc-
tion in GI symptoms—primarily diarrhea/loose bowels,
but also bloating/pain/gas in stomach—are consistent with
previous studies of GI symptom prevalence in patients
treated with a PI [20, 21]. For example, Lalanne et al. [21]
found the rates of nausea (27 vs. 13 %, p = 0.024),
diarrhea (40 vs. 25 %, p = 0.042), and abdominal pain or
bloating (40 vs. 13 %, p = 0.001) were greater in PI- than
non-PI-treated patients.









Description of longitudinal findings
Diarrhea/loose
bowels
4* 4* 4 Switch group decreased prevalence is maintained over the study period
and is significantly lower than baseline from week 4 to week 48
Bloating/pain/gas in
stomach
4* 4 Switch group decreased prevalence is maintained over the study period,
with no further significant changes in prevalence from week 4 to week 48
Pain/numbness/
tingling in hands/feet
4* 4 Switch group decreased prevalence is maintained over the study period,
with no further significant changes in prevalence from week 4 to week 48
Nervous/anxious 4  Decreased prevalence in both groups from week 4 to week 48
Trouble remembering 4 · Switch group initial decrease in prevalence is not maintained over time,
with no differences in prevalence observed between groups from week
4 to week 48
Sad/down/depressed 4 Switch group decreased prevalence from week 4 to week 48
Problems with sex 4 Switch group decreased prevalence from week 4 to week 48
HIV-SI HIV Symptom Index
4 Statistically significant reduction for the switch group,  statistically significant effect for time, · statistically significant time-by-treatment
interaction, * also significant in unadjusted model
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While it was clear that the prevalence of diarrhea/loose
bowels was consistently lower among patients switching to
STB, there were many symptoms that had similar patterns
of prevalence across the two groups and also remained
unchanged from baseline. In adjusted models, prevalence
rates were essentially parallel over time for fatigue, chan-
ges in body, muscle aches/joint pain, skin problems/rash/
itching, weight loss/wasting, nausea, and hair loss. The
importance of the statistically significant associations
found among multiple covariates with these bothersome
symptoms (e.g., race, baseline VACS Index, years since
HIV diagnosis, and years since first antiretroviral therapy)
warrants further investigation and could inform clinicians
which patients are more susceptible to certain symptoms.
A strength of the present study is the use of PRO tools,
which can provide insight into patient-reported symptoms
Fig. 1 Prevalence of significant HIV-SI symptoms over time by treatment group. HIV-SI HIV Symptom Index
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that may be underreported by clinicians [2]. Additionally,
the use of longitudinal modeling allows for a greater
understanding of the prevalence of HIV symptoms over
time after switching antiretroviral therapy. A limitation of
this study is generalizability. The majority of the study
population was male and white, and findings, therefore,
may not be applicable to women and patients of non-white
race. Further, study results are more generalizable to a
virologically suppressed patient population than a treat-
ment-naı¨ve patient population because inclusion criteria
stipulated that all patients have viral loads at baseline that
were undetectable on therapy. Another limitation of our
methodology is the use of imputation for missing items and
acceptance of the most severe (maximum) response when
multiple responses were provided for a single item. It is
possible these methods could result in an inaccurate
reflection of the true patient experience. Finally, it is pos-
sible that given the open-label design, study findings may
be confounded by knowledge of treatment assignment. It is
possible that patients in the no-switch group were more
aware of their symptoms.
Research has shown that switching virologically sup-
pressed patients to STB from an NNRTI ? FTC/TDF was
associated with a reduced prevalence in HIV symptoms as
early as 4 weeks after the switch [17]. This study demon-
strated that switching patients to STB from an RTV-
boosted PI ? FTC/TDF regimen was associated with
reduced prevalence in five HIV symptoms (diarrhea/loose
bowels, bloating/pain/gas in stomach, pain/numbness/tin-
gling in hands/feet, nervous/anxious, and trouble remem-
bering) after 4 weeks, with a sustained decrease in
diarrhea/loose bowels over 48 weeks. These benefits are
important because PI-associated GI side effects may
eventually lead to decreased quality of life and treatment
interruption [18].
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